Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases With First Patient Dosed in Phase 2 TRANQUILITY Trial

– First patient dosed in trial to evaluate the safety, pharmacokinetics and pharmacodynamics of TOUR006 in patients with inflammatory risk and chronic kidney disease – – Topline data anticipated in the first half of

GlobeNewswireMay 16 06:00

Buy Rating Affirmed for Tourmaline Bio Amid Progress in TOUR006 Trials and Expansion Opportunities

TipRanksMay 16 03:07

Truist Financial Reaffirms Their Buy Rating on Tourmaline Bio (TRML)

TipRanksMay 14 09:05

HC Wainwright & Co. Reiterates Buy on Tourmaline Bio, Maintains $48 Price Target

HC Wainwright & Co. analyst Yi Chen reiterates Tourmaline Bio with a Buy and maintains $48 price target.

Analyst UpgradesMay 14 08:57

Analysts Offer Insights on Healthcare Companies: Kura Oncology (KURA) and Tourmaline Bio (TRML)

TipRanksMay 14 08:50

Tourmaline Bio | 10-Q: Quarterly report

SEC announcementMay 13 15:20 · Announcements